Femasys (NASDAQ:FEMY) Earns “Buy” Rating from HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $12.00 target price on the stock.

Separately, Chardan Capital cut their target price on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Femasys Stock Performance

Shares of Femasys stock opened at $1.04 on Wednesday. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. The firm has a 50 day simple moving average of $1.14 and a 200 day simple moving average of $1.13. Femasys has a fifty-two week low of $0.73 and a fifty-two week high of $2.40. The firm has a market cap of $23.81 million, a P/E ratio of -1.28 and a beta of -2.83.

Femasys (NASDAQ:FEMY) last released its earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The firm had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. Sell-side analysts predict that Femasys will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Femasys

A number of institutional investors have recently made changes to their positions in FEMY. CM Management LLC boosted its holdings in Femasys by 6.3% during the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after buying an additional 25,000 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after acquiring an additional 17,473 shares during the last quarter. XTX Topco Ltd raised its position in shares of Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares during the period. Finally, Aljian Capital Management LLC bought a new position in Femasys during the 3rd quarter worth approximately $27,000. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.